# Modified Tapeworm Drug Shows Promise for Endometriosis Treatment Nanotechnology-enhanced niclosamide targets rogue immune cells to reduce endometriosis-related inflammation and lesion growth. - **Source:** [Latest from Live Science](https://www.livescience.com/feeds.xml) - **Published:** 2026-10-14 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/dcb9afe2-8cc4-44d0-9f84-27bf03b6035a ## Endometriosis Treatment Challenges Endometriosis affects 190 million individuals worldwide, causing chronic pelvic pain and infertility. Current hormonal treatments often carry side effects like mood swings, while surgical interventions frequently result in lesion regrowth. With no existing cure, researchers are actively seeking novel therapeutic approaches to manage this understudied and painful chronic condition. ## Targeting Rogue Immune Cells Professor Kanako Hayashi identified specific rogue immune cells within endometrial lesions that drive inflammatory reactions and tissue growth. These cells possess a unique chemical label known as a folate receptor. This specific marker makes them an ideal target for precision drug delivery, potentially bypassing the limitations of systemic hormonal therapies. ## Repurposing Niclosamide Medication Niclosamide, an FDA-approved tapeworm medication, has shown potential in inhibiting endometriosis progression by suppressing inflammatory mechanisms. However, the drug previously faced practical hurdles, including poor water solubility and a short duration in the body. Researchers needed a way to improve its delivery and target specificity to make it viable. ## Nanotechnology Delivery Mechanism Anjali Sharma utilized click chemistry to attach niclosamide to a large, tree-like molecule called a dendrimer. This modification improved solubility in blood. By adding a folate group, the team created a GPS-like system that ensures the drug only releases its payload once it enters the diseased cells, sparing other healthy organs. ## Successful Mouse Model Trials In recent laboratory tests, the modified drug demonstrated high precision by zeroing in on endometrial tissue without accumulating in the liver. A single injection significantly reduced pain symptoms in mice compared to untreated groups. Furthermore, the treatment effectively slowed or entirely halted the growth of new lesions during the study period. ## Clinical Development Roadmap The research team is currently working toward clinical trials to evaluate the treatment in humans. Initial phases will prioritize testing the safety of the nanomedicine in patients. Subsequent trials will then assess its long-term effectiveness in managing endometriosis, building upon the promising results observed in the initial mouse model experiments. ## Expert Perspectives on Repurposing Ioannis Simitsidellis notes that repurposing existing drugs offers significant potential for addressing immune cell dysfunction in endometriosis. While the current findings are a vital stepping stone, he emphasizes the necessity of replicating these results in larger sample sizes. The transition from mouse models to human clinical trials remains the critical next phase. ## Future Research Implications The study highlights the urgent need for better-funded research into endometriosis, a condition that has historically lacked sufficient attention. With hundreds of patients already inquiring about trial participation, the potential for this nanotech-enhanced drug offers hope for a more effective, targeted solution for those suffering from this chronic, hormone-driven disease. ## Sources covering this story - https://www.livescience.com/health/reproductive-health/tapeworm-drug-could-help-treat-endometriosis-mouse-study-hints — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._